Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 30th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
ILMN	ILLUMINA INC	$20.56B	152,900,000	93.48%	6.52%	Net Selling	Net Selling
SHC	SOTERA HEALTH CO	$4.62B	284,392,079	80.24%	19.76%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$52.29B	79,624,034	98.25%	1.75%	Net Buying	Net Selling
A	AGILENT TECHNOLOGIES INC	$34.41B	283,498,871	90.17%	1.26%	Net Selling
RVTY	REVVITY INC	$10.99B	111,799,374	97.24%	2.76%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$23.82B	82,400,000	96.66%	1.56%	Net Selling	Net Selling
TMO	THERMO FISHER SCIENTIFIC INC	$193.58B	371,484,244	99.09%	0.91%	Net Buying	Net Buying
MEDP	MEDPACE HOLDINGS INC	$12.82B	28,381,283	26.66%	73.34%	Net Selling	Net Buying
MTD	METTLER TOLEDO INTERNATIONAL INC	$27.78B	20,325,250	95.41%	4.59%	Net Buying	Net Buying
NEOG	NEOGEN CORP	$2.44B	217,525,981	97.85%	2.15%	Net Buying	Net Buying
BNR	BURNING ROCK BIOTECH LTD	$278.30M	107,741,467	1.59%	0.00%
DHR	DANAHER CORP	$148.95B	707,139,356	76.07%	23.93%	Net Selling	Net Selling
QGEN	QIAGEN NV	$10.84B	217,685,000	68.94%	0.00%
IQV	IQVIA HOLDINGS INC	$30.34B	169,700,000	53.59%	46.41%	Net Selling	Net Selling
PRPO	PRECIPIO INC	$42.19M	1,752,007	0.59%	99.41%	Net Buying	Net Buying
DGX	QUEST DIAGNOSTICS INC	$23.28B	109,866,320	96.37%	1.81%	Net Selling	Net Selling
CAI	CARIS LIFE SCIENCES INC	$5.68B	282,146,923	40.12%	59.88%	Net Selling	Net Buying
WAT	WATERS CORP	$31.33B	98,101,871	58.39%	4.96%	Net Buying	Net Selling
NTRA	NATERA INC	$29.49B	141,731,250	80.42%	19.58%	Net Selling	Net Selling
CDNA	CAREDX INC	$960.82M	51,216,344	76.99%	23.01%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$431.07M	93,508,165	91.28%	8.72%	Net Selling	Net Buying
BLLN	BILLIONTOONE INC	$3.49B	45,768,760	18.67%	26.06%	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.79B	49,227,800	96.64%	3.36%	Net Buying	Net Selling
NEO	NEOGENOMICS INC	$1.28B	129,812,211	72.96%	27.04%	Net Buying	Net Selling
ICLR	ICON PLC	$8.26B	76,359,932	100.00%	0.00%
FLGT	FULGENT GENETICS INC	$478.77M	31,230,632	56.99%	42.12%	Net Selling	Net Selling
CSTL	CASTLE BIOSCIENCES INC	$879.15M	29,731,198	85.86%	14.14%	Net Selling	Net Selling
BDSX	BIODESIX INC	$151.13M	9,858,358	3.92%	96.08%	Net Buying	Net Buying
RDNT	RADNET INC	$5.39B	77,146,342	71.25%	28.75%	Net Selling	Net Buying
MYNZ	MAINZ BIOMED NV	$3.11M	4,091,853	27.66%	44.56%	Net Buying
GRAL	GRAIL INC	$2.08B	38,982,223	76.63%	21.22%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$310.95M	108,345,239	56.41%	43.59%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	$2.88B	61,311,704	88.69%	11.31%	Net Selling	Net Selling
XGN	EXAGEN INC	$82.04M	22,663,099	47.66%	49.00%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	$271.14M	16,034,309	10.85%	0.00%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$172.27M	28,664,437	16.80%	83.20%	Net Buying	Net Buying
GH	GUARDANT HEALTH INC	$12.32B	131,170,441	67.52%	32.48%	Net Selling	Net Selling
LAB	STANDARD BIOTOOLS INC	$434.56M	384,565,414	55.78%	44.22%	Net Buying	Net Buying
OPK	OPKO HEALTH INC	$921.24M	767,701,280	20.24%	79.76%	Net Buying
MDXH	MDXHEALTH SA	$16.83M	49,497,334	25.29%	74.71%
STIM	NEURONETICS INC	$91.77M	68,485,922	61.63%	32.61%	Net Selling	Net Selling
PSNL	PERSONALIS INC	$947.96M	104,631,832	68.98%	31.02%	Net Buying	Net Buying
FONR	FONAR CORP	$121.93M	6,555,521	39.45%	3.60%
MBAI	CHECK-CAP LTD	$247.70M	151,962,777	0.02%	0.00%
NDRA	ENDRA LIFE SCIENCES INC	$4.84M	1,166,441	5.50%	94.50%	Net Buying
ISPC	ISPECIMEN INC	$2.44M	9,771,028	1.30%	66.08%
EXAS	EXACT SCIENCES CORP	$19.73B	190,888,211	84.97%	3.49%	Net Selling	Net Selling
NOTV	INOTIV INC	$9.32M	34,394,971	22.01%	39.39%	Net Selling	Net Selling
XWEL	XWELL INC	$8.59M	5,766,703	1.53%	98.47%
SERA	SERA PROGNOSTICS INC	$88.38M	38,594,793	45.71%	25.16%	Net Selling	Net Selling
TRIB	TRINITY BIOTECH PLC	$13.30M	369,329,458	0.23%	0.00%
VNRX	VOLITIONRX LTD	$26.16M	122,801,572	13.15%	33.09%	Net Buying	Net Selling
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.77M	4,498,709	1.60%	98.40%
DRIO	DARIOHEALTH CORP	$81.02M	6,768,184	5.02%	94.98%	Net Buying
BNBX	BNB PLUS CORP	$3.87M	5,447,469	2.37%	97.63%
ADVB	ADVANCED BIOMED INC	$4.40M	1,082,000	4.08%	0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Mar 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 10 points higher than the diagnostic & research industry average of 27.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 51.13% over the past year, overperforming other diagnostic & research stocks by 40 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 3.08% from Illumina's current stock price of $134.46.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 30, which is 3 points higher than the diagnostic & research industry average of 27.

SHC passed 10 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 32.33% over the past year, overperforming other diagnostic & research stocks by 21 percentage points.

Sotera Health Co has an average 1 year price target of $21.40, an upside of 31.69% from Sotera Health Co's current stock price of $16.25.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 53, which is 26 points higher than the diagnostic & research industry average of 27.

IDXX passed 18 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 48.91% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

Idexx Laboratories has an average 1 year price target of $765.71, an upside of 16.59% from Idexx Laboratories's current stock price of $656.73.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.51%, which is 1 percentage points higher than the diagnostic & research industry average of 0.72%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.1% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.82%, which is the same as the diagnostic & research industry average of 0.72%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.6% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.75%, which is the same as the diagnostic & research industry average of 0.72%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.22% in the last day, and up 0.66% over the last week. Fulgent Genetics was the among the top losers in the diagnostics & research industry, dropping -38.09% yesterday.

Fulgent Genetics shares are trading lower after the company reported mixed Q4 financial results. The company also issued FY26 guidance below estimates.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 84 points higher than the diagnostic & research industry average of 16. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -42.97% in the past year. It has underperformed other stocks in the diagnostic & research industry by -54 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 13 points higher than the diagnostic & research industry average of 16. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 29.69% in the past year. It has overperformed other stocks in the diagnostic & research industry by 19 percentage points.

3. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 29, which is 13 points higher than the diagnostic & research industry average of 16. It passed 2 out of 7 valuation due diligence checks.

Revvity's stock has dropped -10.99% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 20.09% over the next year.

4.76% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 28.57% of diagnostic & research stocks are rated B (Buy), 64.29% are rated C (Hold), 2.38% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 16.26x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.